Loading...
•
Sep 30, 2023
Equillium Q3 2023 Earnings Report
Equillium announced data from Phase 1b EQUALISE study presented at the 2023 Annual Meeting of the American Society of Nephrology.
Key Takeaways
Equillium announced positive data from the Type B portion of the EQUALISE study in lupus nephritis patients. The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added to mycophenolate mofetil (MMF) and corticosteroids.
At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR).
6 of 15 (40%) subjects achieved CR (UPCR < 0.7 g/g) by week 28.
Additional 5 of 15 (33%) subjects achieved PR (UPCR > 50% reduction) by week 28.
Itolizumab demonstrated a favorable safety and tolerability profile.